SCHEMBL6500341

SCHEMBL6500341

Cc1cccc(-c2nc(NC(=O)c3cccnc3)sc2-c2ccnc(F)c2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 8/20 0.68
ADORA1 P30542 5/20 0.68
ADORA2A P29274 2/20 0.68
CHRM5 P08912 1/20 0.68
HTR2A P28223 1/20 0.68
HTR2C P28335 1/20 0.68
ADORA2B P29275 1/20 0.68
DRD4 P21917 1/20 0.63
TSPO P30536 1/20 0.63
DRD3 P35462 1/20 0.63
TMEM97 Q5BJF2 1/20 0.63
MAPK14 Q16539 8/20 0.56
KDM4E B2RXH2 1/20 0.56
ALDH1A1 P00352 1/20 0.56
LMNA P02545 1/20 0.56
POLB P06746 1/20 0.56
IKBKB O14920 1/20 0.53
MAPK13 O15264 1/20 0.53
PRKD3 O94806 1/20 0.53
MAP4K4 O95819 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3892411 0.92 ADORA3 (0.69) ADORA3ADORA1ADORA2ACHRM5HTR2A
SCHEMBL5792342 0.88 MAPK14 (0.74) ADORA3ADORA1ADORA2ACHRM5HTR2A
SCHEMBL5205132 0.84 MAPK14 (0.62) ADORA3ADORA1ADORA2ACHRM5HTR2A
SCHEMBL3890123 0.84 MAPK14 (0.61) ADORA3ADORA1ADORA2ACHRM5HTR2A
SCHEMBL3887439 0.84 ADORA3 (0.81) ADORA3ADORA1ADORA2ACHRM5HTR2A
SCHEMBL5804809 0.83 MAPK14 (0.59) ADORA3ADORA1ADORA2ACHRM5HTR2A
SCHEMBL5805510 0.83 MAPK14 (0.59) ADORA3ADORA1ADORA2ACHRM5HTR2A
SCHEMBL5804807 0.83 MAPK14 (0.59) ADORA3ADORA1ADORA2ACHRM5HTR2A
SCHEMBL3900986 0.83 MAPK14 (0.60) ADORA3ADORA1ADORA2ACHRM5HTR2A
SCHEMBL3888866 0.83 ADORA3 (0.57) ADORA3ADORA1ADORA2ACHRM5HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed
EP-1402900-A1 MEDICINAL COMPOSITIONS Takeda Chemical Industries, Ltd. (JP) 2004-03-31 EP disclosed
US-20040053973-A1 Substituted 1,3-thiazole compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 ADORA3 1613/4885ADORA1 1594/4885ADORA2A 1487/4885
US-20040053973-A1 Substituted 1,3-thiazole compounds, their production and use MAPK1, MAP4K2, MAPK4 ADORA3 3759/4885ADORA1 3999/4885ADORA2A 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.